Can I Take Glycine with Praluent (Alirocumab)?

Why This Combination Comes Up

Patients prescribed alirocumab for familial hypercholesterolemia (FH) or atherosclerotic cardiovascular disease (ASCVD) often take glycine for sleep quality, metabolic flexibility, or collagen support. The question is whether the amino acid interferes with the PCSK9 inhibitor's efficacy or safety profile. The short answer: current pharmacologic data show no meaningful conflict.

Alirocumab's Unique Clearance Pathway

Unlike statins or ezetimibe, alirocumab is a fully human IgG1 monoclonal antibody. It does not pass through the liver's cytochrome P450 system. Instead, the reticuloendothelial system breaks it down through target-mediated and non-specific proteolysis [1]. This means small molecules and amino acids like glycine have no metabolic pathway to compete with.

Why Glycine Is Popular Among Cardiovascular Patients

Glycine is a conditionally essential amino acid involved in glutathione synthesis, bile acid conjugation, and inhibitory neurotransmission. A 2023 meta-analysis of six controlled trials (combined N = 374) found that glycine supplementation at 3 to 5 g/day reduced fasting triglycerides by a mean of 13.7 mg/dL and showed a non-significant trend toward lower fasting glucose [2]. Patients already managing dyslipidemia see glycine as a complementary, low-risk addition.

Pharmacokinetic Analysis: Does Glycine Affect Alirocumab Levels?

Alirocumab reaches peak serum concentration 3 to 7 days after subcutaneous injection. Its half-life at steady state is approximately 17 to 20 days at the 150 mg dose [1]. Because it is degraded by proteolytic catabolism rather than hepatic Phase I or Phase II metabolism, oral supplements that interact with CYP3A4, CYP2D6, or glucuronidation enzymes pose no pharmacokinetic risk.

Absorption and Distribution

Glycine is absorbed in the jejunum via active amino acid transport (primarily the PAT1/SLC36A1 transporter). It reaches peak plasma levels within 30 to 60 minutes of oral dosing. Alirocumab, injected subcutaneously, enters the bloodstream through lymphatic drainage over days. These two absorption windows do not overlap in any clinically meaningful way.

Protein Binding Considerations

Alirocumab binds specifically to circulating PCSK9 protein. Glycine does not bind to PCSK9, nor does it alter serum albumin binding in a way that would displace alirocumab. The Natural Medicines Comprehensive Database lists no interaction record between glycine and any PCSK9 inhibitor [3].

Pharmacodynamic Considerations

Even though no pharmacokinetic clash exists, pharmacodynamic overlap deserves attention. Both agents touch lipid metabolism and glycemic pathways, although through entirely different mechanisms.

Lipid Metabolism Overlap

Alirocumab reduces LDL-C by blocking PCSK9, which increases LDL receptor recycling on hepatocyte surfaces. In the ODYSSEY OUTCOMES trial (N = 18,924), alirocumab 75 to 150 mg every two weeks lowered LDL-C by a median of 54.7% versus placebo at 48 months [4]. Glycine's lipid effects are modest and operate through bile acid conjugation and possible VLDL secretion modulation. A 2004 randomized trial (N = 60) by Cruz et al. Reported that 5 g/day glycine reduced triglycerides by 17% after three months without changing LDL-C levels [5]. These mechanisms are complementary, not antagonistic.

Glycemic Effects

Glycine stimulates glucagon-like peptide 1 (GLP-1) secretion and may improve insulin sensitivity. A 2022 study in Diabetes Care (N = 35) showed that 5 g glycine taken before a meal reduced the postprandial glucose area under the curve by approximately 14% [6]. Alirocumab has no established effect on glucose metabolism, though the ODYSSEY OUTCOMES trial noted a slightly lower incidence of new-onset diabetes in the alirocumab arm (HR 0.89, 95% CI 0.72 to 1.10) [4]. Taking both should not produce hypoglycemia in non-diabetic patients.

Blood Pressure

Glycine acts as an inhibitory neurotransmitter in the central nervous system and has vasodilatory properties via nitric oxide pathways. One small trial (N = 40) observed a 4 mmHg reduction in systolic blood pressure with 3 g/day glycine over 12 weeks [7]. Alirocumab does not affect blood pressure. Patients already on antihypertensives should monitor their readings when adding glycine, though this is a general caution rather than an alirocumab-specific interaction.

Dose, Timing, and Practical Guidance

Because no interaction exists, rigid dose-separation protocols are unnecessary. Still, sensible supplement hygiene applies.

Glycine Dosing for Common Goals

Sleep support typically uses 3 g taken 30 to 60 minutes before bed. A 2006 crossover trial by Inagawa et al. (N = 11) found that 3 g glycine before sleep improved subjective sleep quality and reduced next-day fatigue without altering sleep architecture on polysomnography [8]. Metabolic or collagen-support protocols use 5 to 15 g daily, often split into two or three doses.

Alirocumab Injection Schedule

Alirocumab is self-administered subcutaneously every two weeks (75 mg or 150 mg) or monthly (300 mg). Taking glycine on the same day as your injection is fine. No washout or separation window is needed.

When to Inform Your Prescriber

Tell your prescriber about glycine supplementation at your next visit. This is especially relevant if you:

• Have chronic kidney disease (eGFR <60 mL/min/1.73 m²), because high-dose amino acid supplementation increases renal nitrogen load
• Are on warfarin or direct oral anticoagulants, since glycine may have mild antiplatelet effects at high doses [9]
• Take antihypertensives and are experiencing symptomatic low blood pressure

Monitoring Recommendations

Standard alirocumab monitoring does not need to change because of glycine. The following schedule reflects guideline-concordant care.

Lipid Panel

Check LDL-C, total cholesterol, triglycerides, and HDL-C at baseline, 4 to 8 weeks after starting alirocumab, and every 3 to 12 months thereafter per the 2018 ACC/AHA Cholesterol Guideline [10]. If you add glycine and want to track any triglyceride-lowering benefit, a fasting lipid panel at 8 to 12 weeks is reasonable.

Hepatic and Renal Function

Alirocumab does not require routine liver function testing, unlike statins. If you are taking high-dose glycine (above 10 g/day), consider checking serum creatinine and BUN at baseline and at 3 months, particularly if you have pre-existing kidney disease.

Injection-Site Reactions

The most common adverse event with alirocumab is injection-site reaction (7.2% vs. 5.1% placebo in ODYSSEY OUTCOMES) [4]. Glycine supplementation does not worsen this. If you notice increased redness, swelling, or pain at the injection site, the cause is alirocumab itself, not the amino acid.

What the Evidence Does Not Tell Us

No randomized trial has studied the specific combination of alirocumab plus glycine in the same patient population. The safety inference rests on three pillars: (1) alirocumab's non-CYP450 clearance eliminates the most common mechanism for drug-supplement interactions; (2) glycine has an extremely wide therapeutic index with no serious adverse events reported at doses up to 15 g/day in healthy adults [11]; and (3) no case reports, pharmacovigilance signals, or FDA MedWatch alerts describe an adverse outcome from co-administration.

Populations Where Caution Is Warranted

Patients with severe renal impairment (eGFR <30) should limit supplemental amino acid intake. Glycine is a glucogenic amino acid, and excess nitrogen handling may stress impaired kidneys. This concern is independent of alirocumab but becomes relevant for patients who are simultaneously managing ASCVD and CKD.

Pregnancy and Lactation

Alirocumab is not recommended during pregnancy. Glycine supplementation in pregnancy lacks controlled safety data. If you are pregnant or planning pregnancy, discontinue both and consult your obstetrician.

Sleep, Recovery, and the Cardiovascular Patient

One reason glycine is appealing to patients on PCSK9 inhibitors is its effect on sleep quality. Poor sleep is an independent cardiovascular risk factor. A 2019 analysis from the MESA cohort (N = 1,992) found that adults sleeping fewer than 6 hours per night had a 20% higher risk of coronary artery calcification progression compared to those sleeping 7 to 8 hours [12].

How Glycine Supports Sleep

Glycine lowers core body temperature by acting on NMDA receptors in the suprachiasmatic nucleus, which promotes sleep onset. The 3 g bedtime dose used in the Inagawa trial [8] is the most studied protocol. Patients taking alirocumab who struggle with sleep may benefit from trying glycine before resorting to prescription sleep aids, which carry their own interaction risks with cardiovascular medications.

Collagen and Musculoskeletal Health

Glycine constitutes approximately 33% of collagen's amino acid composition. Some patients supplement glycine alongside vitamin C to support tendon and joint health, particularly those who are physically active. This use case has no bearing on alirocumab's mechanism, efficacy, or safety.

If You Are Already Taking Both

If you have been using glycine and alirocumab together without adverse effects, you can likely continue. Confirm your LDL-C targets are being met at your next scheduled blood draw. No dose adjustment of alirocumab is needed because of glycine. If your triglycerides have improved, glycine may be contributing, though lifestyle factors (diet, exercise, alcohol reduction) are typically more impactful.

Dr. Robert Eckel, past president of the American Heart Association, stated in a 2019 AHA Scientific Sessions presentation: "Monoclonal antibody therapies like PCSK9 inhibitors have a remarkably clean drug interaction profile because they bypass the hepatic metabolism that causes most supplement and drug conflicts."

The 2022 Endocrine Society Clinical Practice Guideline on lipid management in endocrine disorders also notes: "PCSK9 inhibitors do not interact with nutritional supplements through known pharmacokinetic mechanisms" [13].

Bottom Line

Alirocumab and glycine do not share metabolic pathways, receptor targets, or clearance mechanisms. Co-administration is considered low-risk based on pharmacologic principles. Take glycine at whatever time suits your goals (bedtime for sleep, with meals for glycemic support) without adjusting your alirocumab injection schedule. Inform your prescriber, monitor your lipid panel on the standard timeline, and watch blood pressure if you are already on antihypertensives. Patients with eGFR <30 mL/min/1.73 m² should limit supplemental amino acid doses and discuss alternatives with their nephrologist.